Claimed effect · Tesamorelin

Does Tesamorelin help with visceral fat?

A
Grade A — established in humans2 phase 3 RCTs (n=816) · effect size: moderate
Short answerEstablished in humans. 2 phase 3 RCTs (n=816) point the same way: a moderate effect. Pooled phase 3: visceral adipose tissue −15.2% at 26 weeks vs +5% on placebo; effect lost within 26 weeks of stopping.

What the studies show

Pooled phase 3: visceral adipose tissue −15.2% at 26 weeks vs +5% on placebo; effect lost within 26 weeks of stopping.

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1

In context

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone, approved in the United States to reduce excess abdominal fat in people with HIV-associated lipodystrophy. In that population it cuts visceral fat by about 15% over six months, and the fat returns when treatment stops. Its use for general fat loss, muscle or anti-ageing rests on extrapolation from that specific group; there are no trials in healthy adults. It is not authorised in the EU.

Tesamorelin is approved (rx, us). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Tesamorelin proven to help with visceral fat?
Yes, as far as human trials can show it: 2 phase 3 RCTs (n=816). LYO grades this outcome A.
What studies are behind the grade?
Pooled phase 3: visceral adipose tissue −15.2% at 26 weeks vs +5% on placebo; effect lost within 26 weeks of stopping.
Is Tesamorelin approved for this?
Tesamorelin is an approved medicine (Approved (Rx, US)); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Tesamorelin

Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →